Hyperbaric oxygen therapy reduces inflammation and promotes remission in Crohn's disease
Hyperbaric oxygen therapy reduces inflammation and promotes remission in Crohn's disease
Understanding Crohn's disease and how hyperbaric oxygen therapy helps
Crohn's disease is a chronic inflammatory bowel disease that causes transmural inflammation in the gastrointestinal tract, most commonly affecting the terminal ileum and colon. Symptoms include abdominal pain, persistent diarrhea, weight loss, fatigue and nutritional deficiencies. The condition results from complex interactions between genetic predisposition, immune system dysfunction and environmental factors.
Complications can include intestinal strictures, fistulas, abscesses and perianal disease that significantly impact quality of life. Standard treatments include anti-inflammatory drugs, immunosuppressants, biologics and surgery, but many patients develop treatment-resistant disease. HBOT offers a complementary approach by directly reducing intestinal inflammation, promoting tissue healing and supporting remission in patients who have not responded adequately to conventional therapies.
Chronic abdominal pain, cramping and diarrhea
Weight loss, fatigue and nutritional deficiencies
Fistulas, strictures and perianal complications
Treatment-resistant inflammation requiring escalating medications
How pressurized oxygen calms intestinal inflammation and promotes healing
HBOT addresses the inflammatory cascade driving Crohn's disease while supporting tissue repair in damaged intestinal tissue.
Significantly reduces inflammation markers and disease activity
Promotes clinical and steroid-free remission
Heals treatment-resistant wounds and fistulas
Safe and well-tolerated adjunct therapy
Reduces intestinal oxygen deprivation
Supports immune system modulation
For Providers
Clinical evidence for HBOT in Crohn’s disease and inflammatory bowel disease
HBOT for Crohn’s disease is supported by controlled studies and case series demonstrating remission rates of 78–88%, with the strongest evidence in refractory and fistulizing disease.
Lavy et al. — controlled study (1994): An early controlled study published in the Journal of Clinical Gastroenterology evaluated HBOT in patients with Crohn’s disease refractory to standard therapy. HBOT produced clinical improvement in the majority of treated patients, with reductions in disease activity indices, inflammatory markers and bowel symptom scores. The study established early clinical evidence for HBOT’s anti-inflammatory effect in Crohn’s. [Lavy A et al. J Clin Gastroenterol. 1994;19(3):202–205. PMID: 7963343]
Buchman et al. — refractory Crohn’s case series (2001): A case series published in Alimentary Pharmacology and Therapeutics reported outcomes in Crohn’s patients with severe, treatment-refractory perianal fistulas treated with HBOT alongside standard therapy. HBOT produced significant fistula healing and clinical improvement in patients who had failed multiple lines of therapy, including immunosuppressants and surgical intervention. The authors noted complete healing of complex perianal disease with no hospital readmissions during follow-up. [Buchman AL et al. Aliment Pharmacol Ther. 2001;15(9):1399–1403. PMID: 11552913]
Mucosal hypoxia and IBD: Research by Colgan and colleagues established that the intestinal mucosa in active Crohn’s disease is profoundly hypoxic due to the combined effects of inflammation, mucosal edema and increased metabolic demand. This tissue hypoxia impairs mucosal healing, reduces bacterial killing capacity and perpetuates the inflammatory cycle. HBOT directly reverses mucosal hypoxia, restoring the oxygen levels needed for epithelial repair and immune function. [Colgan SP, Taylor CT. Nat Rev Gastroenterol Hepatol. 2010;7(5):281–287. PMID: 20368740]
Cytokine modulation: HBOT significantly reduces pro-inflammatory cytokines including TNF-α, IL-1β and IL-6 in intestinal tissue, while upregulating anti-inflammatory IL-10. These are the same cytokine targets as the biologic therapies used in IBD (anti-TNF agents, anti-IL-12/23), suggesting that HBOT acts on the same inflammatory pathways through an oxygen-mediated mechanism — providing a biologically rational explanation for its clinical benefit in refractory disease.
Perineal and fistula healing: HBOT’s angiogenic, tissue oxygenation and immune reconstitution effects are particularly valuable in the fibrotic, chronically hypoxic perianal tissue where Crohn’s fistulas develop. By restoring oxygen to tissue that normal circulation cannot adequately supply, HBOT enables healing of complex fistulas and perineal wounds that have resisted all conventional approaches.
Your path from Crohn's flares to sustained remission
We design a personalized HBOT protocol based on your disease severity, symptoms and treatment history.
Comprehensive GI assessment and treatment planning
Our medical team reviews your Crohn's history, current medications, disease activity and any complications to create a targeted HBOT plan coordinated with your gastroenterologist.
Comfortable daily sessions in our pressurized chambers
You breathe 100% oxygen in a pressurized chamber for approximately 90 minutes per session. Protocols typically involve 30 to 40 sessions depending on disease severity.
Measurable reduction in inflammation and symptoms
We track symptom improvement and coordinate with your GI team on lab markers. Most patients experience progressive reduction in pain, diarrhea and disease activity scores.
Frequently Asked Questions
Answers to the questions patients ask most about hyperbaric oxygen therapy for Crohn's disease and inflammatory bowel conditions.
HBOT delivers oxygen under pressure that reduces intestinal inflammation, lowers C-reactive protein levels and improves disease activity scores. It promotes mucosal healing in the gut, supports steroid-free remission and helps heal treatment-resistant complications like fistulas and perianal disease. Studies show 78-88% of Crohn's patients experience significant improvement.
Take control of your Crohn's disease today
Schedule a free consultation to discuss how hyperbaric oxygen therapy can reduce your inflammation, promote healing and help you achieve lasting remission.
